Related Experiment Video
Updated: May 10, 2026

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
A new alpha in line between KRAS and NF-κB activation?
1Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53705, USA.
Abstract:
Bang and colleagues report a novel role for GSK-3α, rather than the well-studied GSK-3β, as the link between oncogenic KRAS and the canonical and noncanonical activation pathways of NF-κB in pancreatic cancer. Although the mechanism through which it promotes noncanonical activation remains unclear, the authors show that GSK-3α binds and stabilizes TAK1-TAB complexes to constitutively activate canonical NF-κB signaling. Consequently, the inhibition of GSK-3α retards pancreatic cancer growth in vitro and in vivo, thereby revealing this relatively less-studied kinase as a potential therapeutic target for treatment of KRAS-positive pancreatic cancer.
Insights
Researchers discovered that GSK-3α, not GSK-3β, links KRAS to NF-κB signaling in pancreatic cancer. Inhibiting GSK-3α slowed tumor growth, identifying it as a potential therapeutic target for KRAS-positive pancreatic cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Oncogenic KRAS mutations drive pancreatic ductal adenocarcinoma (PDAC) progression.
- NF-κB signaling pathways are frequently activated in pancreatic cancer, promoting tumor growth and survival.
- GSK-3β is a well-studied kinase, but the role of GSK-3α in cancer remains less understood.
Purpose of the Study:
- To elucidate the role of GSK-3α in mediating the link between oncogenic KRAS and NF-κB activation in pancreatic cancer.
- To investigate the potential of targeting GSK-3α as a therapeutic strategy for KRAS-driven pancreatic cancer.
Main Methods:
- Utilized cell lines and in vivo models of pancreatic cancer.
- Investigated the interaction between GSK-3α, TAK1-TAB complexes, and NF-κB signaling.
- Assessed the effects of GSK-3α inhibition on pancreatic cancer cell proliferation and tumor growth.
Main Results:
- Identified GSK-3α, not GSK-3β, as a key mediator connecting oncogenic KRAS to both canonical and noncanonical NF-κB activation.
- Demonstrated that GSK-3α binds and stabilizes TAK1-TAB complexes, leading to constitutive activation of canonical NF-κB signaling.
- Showed that inhibition of GSK-3α significantly retards pancreatic cancer growth in vitro and in vivo.
Conclusions:
- GSK-3α plays a critical, previously unrecognized role in KRAS-driven pancreatic cancer by regulating NF-κB signaling.
- Targeting GSK-3α represents a promising therapeutic avenue for patients with KRAS-positive pancreatic cancer.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Co-activators and Co-repressors
MAPK Signaling Cascades
Regulation of Nuclear Protein Sorting
TGF - β Signaling Pathway

